Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AMRX Amneal Pharmaceuticals Inc
- Stocks
- Healthcare
- NYSE: AMRX
Price (delayed)
$8.21
Market cap
$2.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.04
Enterprise value
$5.09B
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in
Highlights
AMRX's EPS has soared by 95% year-on-year and by 89% since the previous quarter
The company's net income has surged by 92% YoY and by 89% QoQ
Amneal Pharmaceuticals's equity has shrunk by 107% YoY and by 21% QoQ
AMRX's quick ratio is down by 13% YoY and by 3.8% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amneal.com
Key stats
What are the main financial stats of AMRX
Market
Valuations
Earnings
Shares outstanding
313.42M
Market cap
$2.57B
Enterprise value
$5.09B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.9
EV/EBIT
19.39
EV/EBITDA
10.11
EV/Sales
1.8
Revenue
$2.83B
Gross profit
$1.04B
Operating income
$359.39M
Net income
-$13.05M
EBIT
$262.36M
EBITDA
$503.18M
Free cash flow
$243.04M
Per share
Balance sheet
Liquidity
EPS
-$0.04
EPS diluted
-$0.04
Free cash flow per share
$0.78
Book value per share
-$0.42
Revenue per share
$9.1
TBVPS
$6.68
Total assets
$3.37B
Total liabilities
$3.5B
Debt
$2.58B
Equity
-$131.67M
Working capital
$434.63M
Debt to equity
-19.59
Current ratio
1.4
Quick ratio
0.76
Net debt/EBITDA
5
Margins
Efficiency
Dividend
EBITDA margin
17.8%
Gross margin
36.7%
Net margin
-0.5%
Operating margin
12.7%
Return on assets
-0.4%
Return on equity
N/A
Return on invested capital
7.4%
Return on capital employed
11.5%
Return on sales
9.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMRX stock price
How has the Amneal Pharmaceuticals stock price performed over time
Intraday
1.48%
1 week
0.98%
1 month
12.16%
1 year
27.88%
YTD
3.66%
QTD
1.48%
Financial performance
How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.83B
Gross profit
$1.04B
Operating income
$359.39M
Net income
-$13.05M
Gross margin
36.7%
Net margin
-0.5%
The company's operating income has surged by 153% YoY and by 45% QoQ
The operating margin has surged by 123% year-on-year and by 43% since the previous quarter
AMRX's net margin has surged by 93% year-on-year and by 88% since the previous quarter
The company's net income has surged by 92% YoY and by 89% QoQ
Price vs fundamentals
How does AMRX's price correlate with its fundamentals
Growth
What is Amneal Pharmaceuticals's growth rate over time
Valuation
What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.9
EV/EBIT
19.39
EV/EBITDA
10.11
EV/Sales
1.8
AMRX's EPS has soared by 95% year-on-year and by 89% since the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 107% YoY and by 21% QoQ
The price to sales (P/S) is 125% higher than the 5-year quarterly average of 0.4
AMRX's revenue is up by 13% year-on-year
Efficiency
How efficient is Amneal Pharmaceuticals business performance
The company's return on assets has surged by 91% YoY and by 88% QoQ
AMRX's ROIC has soared by 68% from the previous quarter
AMRX's ROS has soared by 63% since the previous quarter
Dividends
What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMRX.
Financial health
How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 3.8% smaller than its total liabilities
The company's current ratio fell by 15% YoY
AMRX's quick ratio is down by 13% YoY and by 3.8% from the previous quarter
Amneal Pharmaceuticals's equity has shrunk by 107% YoY and by 21% QoQ
The company's debt to equity has surged by 55% YoY and by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.